Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

101.72 +3.92 (+4.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
From BioNTech SE
Via GlobeNewswire
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
From BioNTech SE
Via GlobeNewswire
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
From BioNTech SE
Via GlobeNewswire
BioNTech Completes Acquisition of Biotheus
From BioNTech SE
Via GlobeNewswire
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
BioNTech to Acquire Biotheus to Boost Oncology Strategy
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech to Host Innovation Series R&D Day on November 14, 2024
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
From BioNTech SE
Via GlobeNewswire
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 
Via MarketBeat
Exposures COVID-19 Product Safety
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.